The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...